Children's Tumor Foundation: Neurofibromatosis Type 1 (NF1) Gene Therapy Initiative (Letter of Intent)

The objective of this RFA is to support proof of principle in vitro studies to investigate the feasibility of genome editing techniques, including but not limited to those based on CRISPRCas9, to correct pathogenic mutations in NF1 gene. The ultimate goal of this initiative is to explore the development of genome editing as a potential therapeutic tool for NF1

Funding: $240,000 total (inclusive of 10% indirect costs) for a duration of 2 years.

Only two applications will be selected for funding

http://www.ctf.org/research/gene-therapy-initiative